Kala Bio Inc (KALA)
6.75
-0.03
(-0.43%)
USD |
NASDAQ |
Nov 05, 16:00
6.75
0.00 (0.00%)
After-Hours: 19:03
Kala Bio Enterprise Value: 11.86M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 11.86M |
| November 01, 2024 | 12.83M |
| October 31, 2024 | 13.06M |
| October 30, 2024 | 12.18M |
| October 29, 2024 | 13.75M |
| October 28, 2024 | 13.75M |
| October 25, 2024 | 11.95M |
| October 24, 2024 | 10.80M |
| October 23, 2024 | 8.496M |
| October 22, 2024 | 6.10M |
| October 21, 2024 | 4.764M |
| October 18, 2024 | 4.580M |
| October 17, 2024 | 4.174M |
| October 16, 2024 | 4.856M |
| October 15, 2024 | 4.580M |
| October 14, 2024 | 4.441M |
| October 11, 2024 | 4.898M |
| October 10, 2024 | 4.856M |
| October 09, 2024 | 4.695M |
| October 08, 2024 | 5.086M |
| October 07, 2024 | 5.271M |
| October 04, 2024 | 5.501M |
| October 03, 2024 | 5.040M |
| October 02, 2024 | 5.455M |
| October 01, 2024 | 5.870M |
| Date | Value |
|---|---|
| September 30, 2024 | 6.883M |
| September 27, 2024 | 5.271M |
| September 26, 2024 | 4.810M |
| September 25, 2024 | 5.778M |
| September 24, 2024 | 6.054M |
| September 23, 2024 | 6.791M |
| September 20, 2024 | 7.298M |
| September 19, 2024 | 7.344M |
| September 18, 2024 | 7.344M |
| September 17, 2024 | 7.114M |
| September 16, 2024 | 7.160M |
| September 13, 2024 | 7.851M |
| September 12, 2024 | 8.035M |
| September 11, 2024 | 8.358M |
| September 10, 2024 | 7.851M |
| September 09, 2024 | 8.035M |
| September 06, 2024 | 8.266M |
| September 05, 2024 | 7.574M |
| September 04, 2024 | 8.358M |
| September 03, 2024 | 7.759M |
| August 30, 2024 | 7.575M |
| August 29, 2024 | 7.759M |
| August 28, 2024 | 7.805M |
| August 27, 2024 | 8.542M |
| August 26, 2024 | 8.865M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-8.255M
Minimum
Mar 01 2023
643.29M
Maximum
Jun 02 2020
135.84M
Average
57.93M
Median
Aug 19 2022
Enterprise Value Benchmarks
| CEL-SCI Corp | 50.50M |
| AIM ImmunoTech Inc | 8.843M |
| IGC Pharma Inc | 26.81M |
| NovaBay Pharmaceuticals Inc | 3.645M |
| Protalix BioTherapeutics Inc | 69.53M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.579M |
| Total Expenses (Quarterly) | 8.654M |
| EPS Diluted (Quarterly) | -3.16 |
| Earnings Yield | -206.7% |
| Normalized Earnings Yield | -966.96 |